Literature DB >> 10365892

Rapid effect of lansoprazole on intragastric pH: a crossover comparison with omeprazole.

M Thoring1, H Hedenström, L S Eriksson.   

Abstract

BACKGROUND: The time to onset of acid inhibition is considered an important factor when treating patients with reflux symptoms. This study was therefore designed to investigate the effect of 30 mg lansoprazole and 20 mg omeprazole on gastric pH after single-dose administration.
METHODS: The study was of a randomized, open-label, single-dose and two-way crossover design with a washout period of at least 7 days in between. Fifteen healthy adult male and female subjects were included. The subjects were intubated with a pH catheter. Intragastric pH was measured every 4th sec for 10 min before and during 8 h after drug administration. Blood samples, for determination of plasma concentrations of lansoprazole and omeprazole, were obtained on 10 occasions during 6 h after drug administration. The area under the curve (AUC), the elimination halflife (t1/2), and the peak concentration (Cmax) of the two drugs were calculated.
RESULTS: All subjects completed the study without major complications. The mean pH (0-8 h) after drug administration was 2.9 for lansoprazole and 2.0 for omeprazole (P = 0.0058). A pH of more than 4 was reached for the first time after 130 min with lansoprazole and after 250 min with omeprazole. AUC was 4919 +/- 2526 nmol/l x h for lansoprazole and 1352 +/- 1120 nmol/l x h for omeprazole.
CONCLUSION: Single-dose administration of 30 mg lansoprazole is followed by a rapid absorption of the drug and hence a more efficient acid suppression than after single-dose administration of 20 mg omeprazole in healthy volunteers.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10365892     DOI: 10.1080/003655299750026335

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  6 in total

Review 1.  What is potent acid inhibition, and how can it be achieved?

Authors:  Xavier Calvet; Fernando Gomollón
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  A clinical study to examine the potential effect of lansoprazole on the pharmacokinetics of bosutinib when administered concomitantly to healthy subjects.

Authors:  Richat Abbas; Cathie Leister; Daryl Sonnichsen
Journal:  Clin Drug Investig       Date:  2013-08       Impact factor: 2.859

Review 3.  Lansoprazole: an update of its place in the management of acid-related disorders.

Authors:  A J Matheson; B Jarvis
Journal:  Drugs       Date:  2001       Impact factor: 9.546

4.  Evidence for therapeutic equivalence of lansoprazole 30mg and esomeprazole 40mg in the treatment of erosive oesophagitis.

Authors:  Colin W Howden; E David Ballard; Weining Robieson
Journal:  Clin Drug Investig       Date:  2002       Impact factor: 2.859

5.  Immunoelectron microscopic study for histamine in the gastric enterochromaffin-like cells of rats treated with the proton pump inhibitor lansoprazole.

Authors:  Toshio Tanabe; Ikuo Murata; Midori Karasuyama; Masashi Shin; Ryuichi Ueoka; Kunio Fujiwara
Journal:  Histochem Cell Biol       Date:  2003-10-24       Impact factor: 4.304

6.  Comparator pH study to evaluate the single-dose pharmacodynamics of dual delayed-release dexlansoprazole 60 mg and delayed-release esomeprazole 40 mg.

Authors:  Michael Kukulka; Corey Eisenberg; Sai Nudurupati
Journal:  Clin Exp Gastroenterol       Date:  2011-09-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.